Richard Kha MD , George Burlutsky MAppStat , Aravinda Thiagalingam PhD , Pramesh Kovoor PhD , Joseph Chiha PhD , Paul Mitchell PhD , Gerald Liew PhD
{"title":"Association between Age-Related Macular Degeneration and Mortality in a High Cardiovascular Risk Cohort","authors":"Richard Kha MD , George Burlutsky MAppStat , Aravinda Thiagalingam PhD , Pramesh Kovoor PhD , Joseph Chiha PhD , Paul Mitchell PhD , Gerald Liew PhD","doi":"10.1016/j.oret.2025.02.024","DOIUrl":"10.1016/j.oret.2025.02.024","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate whether age-related macular degeneration (AMD) predicts the risk of all-cause and cardiovascular disease (CVD) mortality in a high CVD risk cohort.</div></div><div><h3>Design</h3><div>Prospective cohort study.</div></div><div><h3>Participants</h3><div>A total of 1545 adult participants who presented to a tertiary Australian hospital for evaluation of acute coronary syndrome were included in this study.</div></div><div><h3>Methods</h3><div><span>Participants were evaluated for acute coronary syndrome using </span>coronary angiography<span><span>. Participants were concurrently examined for AMD from mydriatic<span><span> fundus photographs, which were graded using the Wisconsin grading system into categories of any AMD, early AMD, and late AMD. </span>Coronary artery disease was graded from coronary angiograms using the </span></span>Gensini score<span>. Mortality data were obtained 9 years after baseline examination through data linkage with the Australian National Death Index. Hazard ratios (HRs) were obtained using Cox regression analysis.</span></span></div></div><div><h3>Main Outcome Measures</h3><div>All-cause and CVD mortality data were obtained through data linkage with the Australian National Death Index. Death rates through June 2018 were compared by demographics and potential confounders.</div></div><div><h3>Results</h3><div>Any AMD was identified in 107 (6.9%) participants, including those with early (n = 86) and late AMD (n = 21). Over 9 years of follow-up, 234 (15.1%) participants had died, including 174 (11.3%) participants from fatal CVD events. After controlling for age, sex, body mass index<span>, total cholesterol, smoking status, history of diabetes, hypertension, myocardial infarction, stroke, and macrovascular coronary artery disease severity using the Gensini score, there was an increased rate of all-cause mortality for those with any AMD (HR, 2.37; 95% confidence interval [CI], 1.54–3.64), early AMD (HR, 2.42; 95% CI, 1.48–3.94), and late AMD (HR, 2.25; 95% CI, 1.08–4.71). Any AMD (HR, 2.62; 95% CI, 1.61–4.26) and early AMD (HR, 2.61; 95% CI, 1.50–4.64) were also associated with a greater likelihood of CVD mortality. Late AMD was not associated with CVD mortality.</span></div></div><div><h3>Conclusions</h3><div>In individuals with high CVD risk, the presence of AMD at any stage independently predicted increased all-cause mortality. Meanwhile, any AMD and early AMD increased the risk of CVD mortality. Although mechanisms are unclear, this potentially reflects shared pathways between AMD and CVD.</div></div><div><h3>Financial Disclosure(s)</h3><div>The authors have no proprietary or commercial interest in any materials discussed in this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 9","pages":"Pages 821-827"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Extensive Myelinated Nerve Fibers in a Case of Straatsma Syndrome","authors":"Gulshan Barwar DNB, DOMS","doi":"10.1016/j.oret.2025.01.005","DOIUrl":"10.1016/j.oret.2025.01.005","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 9","pages":"Page e87"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yannik Laich MD , Michalis Georgiou MD, PhD , Kaoru Fujinami MD, PhD , Malena Daich Varela MD, PhD , Yu Fujinami-Yokokawa MPH , Shaima Awadh Hashem MD , Thales A.C. de Guimaraes MD, PhD , Omar A. Mahroo PhD, FRCOphth , Andrew R. Webster MD(Res), FRCOphth , Michel Michaelides MD(Res), FRCOphth
{"title":"Best Vitelliform Macular Dystrophy Natural History Study Report 2","authors":"Yannik Laich MD , Michalis Georgiou MD, PhD , Kaoru Fujinami MD, PhD , Malena Daich Varela MD, PhD , Yu Fujinami-Yokokawa MPH , Shaima Awadh Hashem MD , Thales A.C. de Guimaraes MD, PhD , Omar A. Mahroo PhD, FRCOphth , Andrew R. Webster MD(Res), FRCOphth , Michel Michaelides MD(Res), FRCOphth","doi":"10.1016/j.oret.2025.03.004","DOIUrl":"10.1016/j.oret.2025.03.004","url":null,"abstract":"<div><h3>Purpose</h3><div>To analyze the retinal imaging findings and natural history of Best vitelliform macular dystrophy (BVMD).</div></div><div><h3>Design</h3><div>Single-center retrospective, consecutive, observational study.</div></div><div><h3>Participants</h3><div>Patients with a clinical diagnosis of BVMD, from pedigrees with a likely disease-causing monoallelic variant in <em>BEST1</em>.</div></div><div><h3>Methods</h3><div>Data were extracted from electronic and physical case notes. Retinal imaging with OCT and fundus autofluorescence (FAF) was analyzed cross-sectionally and longitudinally.</div></div><div><h3>Main Outcome Measures</h3><div>Qualitative and quantitative OCT and FAF analysis.</div></div><div><h3>Results</h3><div>Two hundred twenty-two patients (127 men) from 141 families were included. Mean central retinal thickness on OCT at baseline was 337.2 μm for the right eye and 341.1 μm for the left eye, with a mean annual thickness loss of 5.7 and 5.2 μm, respectively. The presence of the OCT features: previtelliform lesion, solid vitelliform lesion, vitelliform lesion with subretinal fluid, and focal choroidal excavation were associated with a better mean visual acuity (VA), whereas the presence of intraretinal fluid and atrophy/fibrosis were correlated with a worse mean VA. Fundus autofluorescence showed an area of hyperautofluorescence at the posterior pole in 138 eyes (34.7%), a circumscribed area of hyperautofluorescence superior or superotemporal of the optic nerve head in 53 eyes (13.3%), fibrotic changes in 48 eyes (12.1%), and atrophy in 41 eyes (10.3%).</div></div><div><h3>Conclusions</h3><div>Best vitelliform macular dystrophy shows a wide spectrum of phenotypes on OCT and FAF imaging. The slow and variable disease course may pose a challenge in identification of early end points for therapeutic trials aimed at altering kinetics of degeneration.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosures may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 9","pages":"Pages 899-907"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gabriela Grimaldi MD , Aude Ambresin MD , Isabel B. Pfister PhD , Christin Schild PhD , Christina Plasencia MD , Katja Hatz MD, PhD , Richard Stillenmunkes MD , Marion R. Munk MD , Arianna Paris MD , Moreno Menghini MD , Dmitri Artemiev MD , Andreas Ebneter MD, PhD , Jennifer Cattaneo MD , Eva C. de Oliveira Figueiredo PhD , Chiara M. Eandi MD, PhD , Jacqueline Fröhlich MD , Nicolas Feltgen MD, PhD , Tahm Spitznagel MD , Gábor Márk Somfai MD, PhD , Mariano Cozzi MD , Justus G. Garweg MD, PhD
{"title":"One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration","authors":"Gabriela Grimaldi MD , Aude Ambresin MD , Isabel B. Pfister PhD , Christin Schild PhD , Christina Plasencia MD , Katja Hatz MD, PhD , Richard Stillenmunkes MD , Marion R. Munk MD , Arianna Paris MD , Moreno Menghini MD , Dmitri Artemiev MD , Andreas Ebneter MD, PhD , Jennifer Cattaneo MD , Eva C. de Oliveira Figueiredo PhD , Chiara M. Eandi MD, PhD , Jacqueline Fröhlich MD , Nicolas Feltgen MD, PhD , Tahm Spitznagel MD , Gábor Márk Somfai MD, PhD , Mariano Cozzi MD , Justus G. Garweg MD, PhD","doi":"10.1016/j.oret.2025.03.015","DOIUrl":"10.1016/j.oret.2025.03.015","url":null,"abstract":"<div><h3>Purpose</h3><div>To report the efficacy and safety of switching to faricimab in a real-world, Swiss cohort of patients with pretreated neovascular age-related macular degeneration (nAMD).</div></div><div><h3>Design</h3><div>Retrospective, multicenter, longitudinal observational study conducted at 11 centers of the Swiss Retina Research Network.</div></div><div><h3>Subjects</h3><div>We included 353 eyes of 325 patients who were switched to intravitreal faricimab after prior anti-VEGF therapy and followed for a minimum of 12 months between May 1, 2022, and October 30, 2024.</div></div><div><h3>Methods</h3><div>Demographic characteristics, baseline functional and OCT findings, treatment history, and outcomes at 12 months after switch to faricimab were extracted from the patients’ electronic case report forms.</div></div><div><h3>Main Outcome Measures</h3><div>Change in best-corrected visual acuity (BCVA), central subfield thickness (CST), presence of retinal fluid (RF) and pigment epithelial detachment, treatment intervals, and safety signals.</div></div><div><h3>Results</h3><div>Twelve months after switch, mean BCVA remained unchanged, whereas mean CST decreased from 315.3 to 263.9 μm (<em>P</em> < 0.01). Fast drying (absence of RF) after 1 faricimab injection was observed in 134 eyes (38%) and correlated positively with the treatment interval at 12 months (<em>r</em>(301) = 0.24; <em>P</em><span> < 0.01). After 12 months, 169 (47.9%) eyes demonstrated the absence of RF compared with 10.2% at switch. Mean treatment interval increased from 5.8 ± 2.5 weeks at switch to 8.3 ± 4.2 weeks at 12 months, and extended treatment intervals (≥12 week) were achieved in 20% of patients. Mild intraocular inflammation was reported in 1.7% of cases.</span></div></div><div><h3>Conclusions</h3><div>Switching to faricimab in pretreated nAMD led to sustained anatomic improvements and stabilization of BCVA, with a substantial reduction in RF compared with baseline. Our results suggest the potential benefits of this switching strategy based on real-world data.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 9","pages":"Pages 838-847"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Iris Pearls in Lepromatous Leprosy.","authors":"Fazal Mohammed Khan, Priyanka, Mohammed Sabir","doi":"10.1016/j.oret.2025.07.010","DOIUrl":"https://doi.org/10.1016/j.oret.2025.07.010","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144963707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Transient Visual Loss Captured by an Ultra-widefield Fundus Camera.","authors":"Xiaoli Xiang","doi":"10.1016/j.oret.2025.07.020","DOIUrl":"https://doi.org/10.1016/j.oret.2025.07.020","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144963713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}